EGFR and non-small cell lung carcinoma: As we mentioned before, the current study demonstrated that radiological response in bone metastases from patients with NSCLC harboring EGFR-TKIs sensitizing mutation to gefitinib treatment without RT was PR or better in 94% and CR in 31% of cases.